180 related articles for article (PubMed ID: 33375117)
1. Pharmacological Inhibition of mTORC2 Reduces Migration and Metastasis in Melanoma.
Guenzle J; Akasaka H; Joechle K; Reichardt W; Venkatasamy A; Hoeppner J; Hellerbrand C; Fichtner-Feigl S; Lang SA
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375117
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.
Schmidt KM; Dietrich P; Hackl C; Guenzle J; Bronsert P; Wagner C; Fichtner-Feigl S; Schlitt HJ; Geissler EK; Hellerbrand C; Lang SA
Neoplasia; 2018 Dec; 20(12):1198-1208. PubMed ID: 30404068
[TBL] [Abstract][Full Text] [Related]
3. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.
Zhang Q; Zhang Y; Chen Y; Qian J; Zhang X; Yu K
Clin Cancer Res; 2019 Jun; 25(12):3630-3642. PubMed ID: 30796032
[TBL] [Abstract][Full Text] [Related]
4. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
[TBL] [Abstract][Full Text] [Related]
5. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.
Kim JO; Kim KH; Song IS; Cheon KS; Kim OH; Lee SC; Lee SK; Kim SJ
Oncotarget; 2017 Jan; 8(2):2936-2948. PubMed ID: 27935857
[TBL] [Abstract][Full Text] [Related]
7. Licochalcone D induces apoptosis and inhibits migration and invasion in human melanoma A375 cells.
Si L; Yan X; Hao W; Ma X; Ren H; Ren B; Li D; Dong Z; Zheng Q
Oncol Rep; 2018 May; 39(5):2160-2170. PubMed ID: 29565458
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
9. mTORC2 regulates hedgehog pathway activity by promoting stability to Gli2 protein and its nuclear translocation.
Maiti S; Mondal S; Satyavarapu EM; Mandal C
Cell Death Dis; 2017 Jul; 8(7):e2926. PubMed ID: 28703798
[TBL] [Abstract][Full Text] [Related]
10. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Werfel TA; Wang S; Jackson MA; Kavanaugh TE; Joly MM; Lee LH; Hicks DJ; Sanchez V; Ericsson PG; Kilchrist KV; Dimobi SC; Sarett SM; Brantley-Sieders DM; Cook RS; Duvall CL
Cancer Res; 2018 Apr; 78(7):1845-1858. PubMed ID: 29358172
[TBL] [Abstract][Full Text] [Related]
11. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Wei BR; Hoover SB; Peer CJ; Dwyer JE; Adissu HA; Shankarappa P; Yang H; Lee M; Peat TJ; Figg WD; Simpson RM
Mol Cancer Ther; 2020 Nov; 19(11):2308-2318. PubMed ID: 32943547
[TBL] [Abstract][Full Text] [Related]
13. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
14. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
15. Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells.
Koch A; Lang SA; Wild PJ; Gantner S; Mahli A; Spanier G; Berneburg M; Müller M; Bosserhoff AK; Hellerbrand C
Oncotarget; 2015 Oct; 6(32):32748-60. PubMed ID: 26293674
[TBL] [Abstract][Full Text] [Related]
16. The thiirane-based selective MT1-MMP/MMP2 inhibitor ND-322 reduces melanoma tumor growth and delays metastatic dissemination.
Marusak C; Bayles I; Ma J; Gooyit M; Gao M; Chang M; Bedogni B
Pharmacol Res; 2016 Nov; 113(Pt A):515-520. PubMed ID: 27687955
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
18. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling.
Chen XY; Li DF; Han JC; Wang B; Dong ZP; Yu LN; Pan ZH; Qu CJ; Chen Y; Sun SG; Zheng QS
Oncotarget; 2017 May; 8(21):34565-34575. PubMed ID: 28410220
[TBL] [Abstract][Full Text] [Related]
20. M2 polarization of macrophages by Oncostatin M in hypoxic tumor microenvironment is mediated by mTORC2 and promotes tumor growth and metastasis.
Shrivastava R; Asif M; Singh V; Dubey P; Ahmad Malik S; Lone MU; Tewari BN; Baghel KS; Pal S; Nagar GK; Chattopadhyay N; Bhadauria S
Cytokine; 2019 Jun; 118():130-143. PubMed ID: 29625858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
